Why the study?
What are the population pharmacokinetic parameters of high-dose methotrexate in Japanese adult patients with malignancies?
Population
51 Japanese adult patients with malignancies (contributing 348 serum samples and 416 urine samples)
Design
Other
Key result
A population pharmacokinetic model for high-dose methotrexate identified creatinine clearance and dose as the most significant factors affecting renal and non-renal clearance, respectively.
Authors
Loading...
May support MTX dosing via CCR and dose; leaves open prospective validation before clinical use.
Observational (n=60)
What are the population pharmacokinetic parameters of high-dose methotrexate in Japanese adult patients with malignancies?
A newly developed population pharmacokinetic model for high-dose methotrexate incorporating serum and urine data improves the prediction of serum concentrations to help control toxic events in Japanese adult patients.
Fukuhara et al. (2008) conducted an observational in Malignancies (n=60). High-dose methotrexate was evaluated on Population pharmacokinetic model parameters (renal and non-renal clearance). A population pharmacokinetic model for high-dose methotrexate identified creatinine clearance and dose as the most significant factors affecting renal and non-renal clearance, respectively.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: